Albina V. Dobrotok

Albina V. Dobrotok

Auto-generated profile, based on publicly available information

Albina V. Dobrotok

Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
NVNato V. Vashakmadze
Nato V. Vashakmadze
NZNatalia V. Zhurkova
Natalia V. Zhurkova
MBMarina A. Babaykina
Marina A. Babaykina
ADAlbina V. Dobrotok
Albina V. Dobrotok
OGOlga B. Gordeeva
Olga B. Gordeeva
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
Background. Hurler syndrome (mucopolysaccharidosis, type I) is a rare hereditary disease with chronic course. The main methods for Hurler syndrome management are hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). In recent years, combination treatment (ERT administration both before and after HSCT) has shown its efficacy in case of disease progression. Clinical case description. The presented clinical cases demonstrate the efficacy of ERT administration in patients with Hurler syndrome after HSCT: in the first clinical case due to the decrease in alpha-iduronidase activity 2 years after HSCT, in the second clinical case due to the aggravation of the patient's condition (cardiovascular and respiratory systems, hepatomegaly, although the level of enzyme and glycosaminoglycans in the patient's urine remained within normal values). Conclusion. Combination treatment including ERT not only before HSCT, but also in case of clinical state worsening after HSCT, plays significant role in stabilizing the patient's condition, preventing rapid progression of symptoms and development of life-threatening complications (especially cardiovascular ones).

15 August 2024 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
OGOlga B. Gordeeva
Olga B. Gordeeva
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
ADAlbina V. Dobrotok
Albina V. Dobrotok
NANatalia L. Aleshenko
Natalia L. Aleshenko
Background. There is evidence that platelet dysfunction in new-type coronavirus infection can lead to both thrombotic and hemorrhagic events: hypercoagulation syndrome leading to thrombosis is one of the most threatening complications of COVID-19; equally important is the hemorrhagic syndrome that can be observed after this disease. The study of platelet aggregation function in children with new-onset coronavirus infection is highly relevant: the results of aggregometry in pediatric practice may help to predict the development of complications from vascular and platelet hemostasis. Aims — to evaluate the direction of changes in platelet haemostasis in children undergoing COVID-19. Methods. In the first phase of the work, we clarified the normal values of platelet aggregation in children with different inducers in whole blood by impedance testing (based on examination data from 105 conditionally healthy children who had not had COVID-19). At the second (main) phase of the study we conducted a single-stage prospective study including 250 pediatric patients residing in the Russian Federation: 143 children suffered mild COVID-19, while the comparison group consisted of 107 patients who had not been ill with a new-type coronavirus infection. All children (those who had COVID-19 and those who had no disease) underwent a comprehensive examination, which included: physical examination, aggregometry and laboratory tests (to rule out acute inflammatory process and hemogram abnormalities potentially affecting platelet aggregation rates). Results. Almost half of the patients after COVID-19 had platelet aggregation abnormalities. At the same time, in every third child there were combined multidirectional disorders in the form of hypo- and hyperaggregation with different inducers, in contrast to the group of children who did not have COVID19 (p 0.05). In the COVID19 group aggregation abnormalities with arachidonic acid were most frequently detected: almost every second patient had hyperaggregation and every fourth patient had hypoaggregation, which was statistically significantly different from the non-disease group (p 0.05). Analysis of the results depending on the time interval after the disease (1–3 months, 3–6, 6–12 months, more than 12 months) showed platelet hyperaggregation with all inducers at 1–3 months, and there was a tendency to reduce aggregation with thrombin and ADP, but hyperaggregation with arachidonic acid persisted for one year after the disease. At an interval of more than one year after COVID-19 every second patient showed a decrease in platelet function (hypoaggregation with all inducers). No statistically significant differences by gender were observed depending on the time interval after the infection. Conclusions. The results of the study demonstrate the vectors of impaired vascular and platelet hemostasis in children with mild COVID-19: The time intervals of platelet dysfunction after the disease have been determined. The results of the study may help to develop a surveillance strategy for children who have had a new type of coronavirus infection to prevent the development of complications from vascular and platelet hemostasis.

20 January 2026 in Pediatric pharmacology
Verified
Journal Article
Closed access
SFSadig T. Fatullaev
Sadig T. Fatullaev
ASAndrey N. Surkov
Andrey N. Surkov
OGOlga B. Gordeeva
Olga B. Gordeeva
NINataliya A. Izotova
Nataliya A. Izotova
EBEvgeniy E. Bessonov
Evgeniy E. Bessonov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
The aim of the study is to evaluate the diagnostic information value of direct serological biomarkers — hyaluronic acid (HA), collagen types I and III (COL1, COL3), growth differentiation factor-15 (GDF-15), monocyte chemotactic factor-1 (MCP-1) and extracellular matrix protein 1 (ECM1) — for noninvasive stage identification hepatic fibrosis (HF) in children. Material and methods . The study included 60 patients (average age 10.2 ± 4.7 years) with chronic liver diseases of various etiologies, including autoimmune hepatitis (16), primary sclerosing cholangitis (11), glycogen disease (10), Wilson’s disease (6), and unspecified HF (17). All children underwent ultrasound examination of the abdominal organs with two-dimensional shear wave elastography (2D-SWE) and quantitative determination of the above markers in the blood serum. The concentrations of HA in the blood serum of patients were determined by enzyme-linked immunosorbent assay (ELISA); COL1, COL3, ECM1, GDF-15 and MCP-1 were determined by sandwich ELISA. Results. The concentrations of HA and GDF-15 in blood serum increased statistically significantly with the progression of HF (p < 0.001; p = 0.001, respectively). To determine the threshold values of HA depending on the stages of HF, high sensitivity (90%) and specificity (up to 100%) were obtained, and the best values of the area under the ROC-curve were used to distinguish the late stages of fibrosis (AUC up to 0.965). The concentrations of GDF-15 in serum are characterized by maximum sensitivity when determining cut-off values to determine the stage of severe fibrosis and its initial manifestations, the specificity for close stages was lower (up to 70%). The concentrations of COL1, COL3, MCP-1, and ECM1 did not show significant differences between the HF stages (p = 0.108; p = 0.455; p = 0.158; p = 0.058, respectively). Direct correlations were found between serum levels of COL1 and COL3 (p = 0.341, p = 0.008), HA and GDF15 (p = 0.592, p < 0.001), MCP-1 and COL3 (p = 0.443, p < 0.001), as well as HA and GDF-15 with the results of 2D-SWE (p = 0.534, p < 0.001; p = 0.505, p < 0.001, respectively). Conclusion . Determination of HA and GDF-15 concentrations can be considered as a valuable prognostic tool for noninvasive HF stratification in children. The usage of these indicators as part of diagnostic algorithms can help to more accurately determine the stage and dynamics of fibrosis, allowing in some cases to abandon invasive methods such as biopsy.

1 March 2023 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
OGOlga B. Gordeeva
Olga B. Gordeeva
ADAlbina V. Dobrotok
Albina V. Dobrotok
LSLiliia R. Selimzianova
Liliia R. Selimzianova
VDValeria A. Deeva
Valeria A. Deeva
Background. Purpura fulminans (PF) – is an acute rapidly progressive thrombosis of small-diameter blood vessels located mainly on the skin of the extremities. PF is characterized by high mortality rates. Patients can have serious consequences, including amputations and loss of fingers, foots or even extremities in general.Clinical case description. A clinical case of developing transient deficiency of protein S complicated by idiopathic PF on the 7th day after acute otitis in a 3-year-old boy due to past infection is presented. The progression of the disease developed within a few hours. The patient became hemorrhagic elements on the skin of extremities, and later — tissue necrosis. The conducted therapy facilitated to stop the pathological process in the form of PF, and also prevented the development of severe disabling complications in the child.Conclusion. Differential diagnosis and treatment should be fast and accurate, as the development of PF occurs in mere hours. Diagnostics should include expanded panel of coagulological tests and instrumental examinations, which determines the justifiability of a multidisciplinary approach in the patient management with disorders in the hemostatic system.

20 January 2026 in Pediatric pharmacology
Verified
Journal Article
Closed access
ASAndrey N. Surkov
Andrey N. Surkov
OGOlga B. Gordeeva
Olga B. Gordeeva
OKOlga E. Krasnova
Olga E. Krasnova
SFSadig T. Fatullaev
Sadig T. Fatullaev
NINatalya A. Izotova
Natalya A. Izotova
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
Objective. The aim of the study is to evaluate diagnostic significance of human leucine-rich alpha-2 glycoprotein (LRG) for noninvasive diagnosis of inflammatory bowel disease (IBD) activity in children. Methods. The study included 60 patients with IBD (Crohn’s disease — 33, ulcerative colitis — 27) who were examined in 2023–2025. The average age was 9.7 ± 4.9 years. Serum LRG levels were measured via enzyme-linked immunosorbent assay (ELISA), “sandwich method”, AssayPro kit, USA. Disease activity was evaluated with specific pediatric indices PUCAI and PCDAI. We have additionally analyzed several immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), IgG, IgM, IgA), as well as standard clinical and laboratory parameters. All the data is presented as median, lower, and upper quartiles (Q1; Q3). We have used Kruskall – Wallis test for comparison of three or more groups, Dunn test with Holm correction for post hoc comparisons, Mann – Whitney U test for comparison of the two groups. The correlation between variables was estimated via Spearman’s rank correlation coefficient (ρ); differences at p < 0.05 were considered statistically significant. Results. Serum LRG levels were statistically significantly higher in patients with high inflammatory activity compared to mild to moderate IBD activity according to PUCAI (p = 0.038) and PCDAI (p = 0.021) scales. The most profound differences were revealed when stratified by the degree of disease clinical activity. Statistically significant positive correlations were also mentioned between serum LRG levels and PUCAI (ρ = 0.556, p = 0.021) and PCDAI (ρ = 0.902, p = 0.001) activity indices, as well as with serum ASCA levels (ρ = 0.314, p = 0.039). Conclusion. Serum LRG level is obviously an informative laboratory marker of IBD activity in children and can be recommended for implementation in comprehensive laboratory diagnostics and monitoring of therapy efficacy along with generally accepted indices and immunological indicators.

24 February 2024 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
OGOlga B. Gordeeva
Olga B. Gordeeva
ADAlbina V. Dobrotok
Albina V. Dobrotok
MVMariia V. Volkova
Mariia V. Volkova
NANatalia L. Aleshenko
Natalia L. Aleshenko
VKVladimir S. Kargin
Vladimir S. Kargin
ИДИ. Джгаркава
И. Джгаркава
Background. Early diagnosis of thrombocytopathies in children is a relevant objective of pediatrics. Diagnostics helps prevent the development of bleeding, chronic posthemorrhagic anemia, reduces the risk of thrombosis.The aim of the study is an assessment of the incidence of platelet aggregation disorders in children with manifestations of hemorrhagic syndrome against the background of chronic pathology.Methods. The study was conducted on the basis of the Research Institute of Pediatrics and Children’s Health, Scientific Center No. 2, Petrovsky National Research Centre of Surgery in the period from January — until December 2022. 62 children were included in the study, of which 50 children were selected (21 boys and 29 girls) aged 2 years 3 months to 17 years 11 months. The median age was 9.4 (7.2; 13.4). Aggregometry was performed using an impedance semiautomatic aggregometer in whole blood.Results. Depending on the diagnosis, the children were divided into the following groups: cardiovascular diseases (CVD), lysosomal storage disorders (LSD), monogenic hereditary diseases (MHD), children with dysplastic syndrome (DS), children with pathology of the nervous system (NS). Hypoaggregation with thrombin-activating peptide (TRAP test) was detected in 28% of cases (n = 14), more often in children from the group with MHD — 10% (n = 5) and with the presenceof DS — 10% (n = 5). Hypoaggregation with adenosine diphosphate (ADP test) was detected in 20% of cases (n = 10), with arachidonic acid (ASPI test) was detected in 14% (n = 7). Hyperaggregation with the TRAP test was detected in 12% (n = 6), with the ADP test detected in 8% of cases (n = 4). Hyperaggregation with ASPI test was detected in 18% of cases (n = 9).Conclusion. The analyzed results of laboratory tests of platelet aggregation function, hypoaggregation with inducers was observed in more than half of the children, hyperaggregation was observed was present in almost half of the patients.